IRIS UniCatt

De Sanctis, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.533
NA - Nord America 2.436
AS - Asia 2.156
SA - Sud America 486
AF - Africa 69
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 7.690
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.318
SG - Singapore 1.107
DE - Germania 802
IT - Italia 578
CN - Cina 482
BR - Brasile 406
SE - Svezia 339
FR - Francia 141
IE - Irlanda 135
GB - Regno Unito 116
VN - Vietnam 91
IN - India 89
FI - Finlandia 69
ID - Indonesia 68
RU - Federazione Russa 66
CA - Canada 59
HK - Hong Kong 50
NL - Olanda 46
TR - Turchia 40
PL - Polonia 39
KR - Corea 37
ES - Italia 35
MX - Messico 35
BD - Bangladesh 34
AR - Argentina 33
JP - Giappone 32
UA - Ucraina 29
ZA - Sudafrica 22
AT - Austria 21
IQ - Iraq 18
CZ - Repubblica Ceca 16
PK - Pakistan 16
IR - Iran 14
BE - Belgio 13
MK - Macedonia 13
AE - Emirati Arabi Uniti 12
CO - Colombia 12
EG - Egitto 12
CI - Costa d'Avorio 11
EC - Ecuador 11
IL - Israele 11
LT - Lituania 11
RS - Serbia 11
CH - Svizzera 10
SA - Arabia Saudita 9
JO - Giordania 7
PA - Panama 7
RO - Romania 7
VE - Venezuela 7
PT - Portogallo 6
MA - Marocco 5
PH - Filippine 5
PY - Paraguay 5
SK - Slovacchia (Repubblica Slovacca) 5
UZ - Uzbekistan 5
BG - Bulgaria 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
MY - Malesia 4
PE - Perù 4
UY - Uruguay 4
AU - Australia 3
CL - Cile 3
HR - Croazia 3
KE - Kenya 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
SN - Senegal 3
TN - Tunisia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AO - Angola 2
BT - Bhutan 2
BY - Bielorussia 2
CR - Costa Rica 2
DM - Dominica 2
DZ - Algeria 2
GR - Grecia 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
NP - Nepal 2
OM - Oman 2
TH - Thailandia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
EE - Estonia 1
GE - Georgia 1
GL - Groenlandia 1
GT - Guatemala 1
GY - Guiana 1
HU - Ungheria 1
Totale 7.675
Salva come PNG Salva come JPEG
Città #
Singapore 580
Ashburn 388
Chandler 332
Frankfurt am Main 145
New York 143
Beijing 107
Dublin 107
Rome 107
Hefei 105
Los Angeles 95
Milan 90
Dallas 68
Jakarta 64
Munich 56
Hong Kong 46
São Paulo 45
Boston 40
San Mateo 38
Helsinki 36
Seoul 35
Marseille 33
Moscow 32
Ho Chi Minh City 30
Houston 29
Princeton 28
Kent 27
Tokyo 27
Nuremberg 25
Palermo 24
Warsaw 24
Buffalo 23
Denver 23
Atlanta 22
Poplar 22
Santa Clara 22
Stockholm 21
Hanoi 20
Montreal 20
Orem 20
Toronto 20
Ann Arbor 19
Chicago 19
Düsseldorf 19
Dearborn 18
The Dalles 18
Wilmington 18
Bremen 17
Chennai 16
Mexico City 16
San Francisco 16
Turku 16
Brooklyn 15
Johannesburg 15
London 15
Amsterdam 14
Cattolica 14
Nanjing 14
Nürnberg 14
Pune 14
Augusta 13
Boardman 13
Brno 13
Falkenstein 13
Paris 13
Ankara 12
Brussels 12
Seattle 12
Vienna 12
Abidjan 11
Belo Horizonte 11
Kish 11
Rio de Janeiro 11
Jacksonville 10
Lancaster 10
Manchester 10
Redwood City 10
Salamanca 10
Secaucus 10
Skopje 10
Bologna 9
Lappeenranta 9
Phoenix 9
Shanghai 9
Bari 8
Menlo Park 8
Turin 8
Wroclaw 8
Amman 7
Andover 7
Baghdad 7
Brasília 7
Charlotte 7
Dhaka 7
Hebei 7
Izmir 7
Mumbai 7
Porto Alegre 7
Washington 7
Woodbridge 7
Bexley 6
Totale 3.811
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 573
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 293
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 284
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 175
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 165
Developmental milestones in type I spinal muscular atrophy 161
Assessing floppy infants: a new module 153
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 138
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 137
Revised upper limb module for spinal muscular atrophy: Development of a new module 134
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 134
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 133
Predominant distal muscle involvement in spinal muscular atrophy 130
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 128
Longitudinal assessments in discordant twins with SMA 124
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 122
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 119
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 118
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 117
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 116
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 116
De novo partial 13q22-q34 trisomy with typical neurological and immunological findings: A case report with new genetic insights 115
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 115
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 114
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 113
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 112
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 111
Nusinersen in type 0 spinal muscular atrophy: should we treat? 110
Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen 109
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 107
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 106
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 106
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 104
Early treatment of type II SMA slows rate of progression of scoliosis 103
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 103
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 103
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 102
Developmental milestones in type I spinal muscular atrophy 100
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 95
Clinical Variability in Spinal Muscular Atrophy Type III. 94
Revised upper limb module for spinal muscular atrophy: Development of a new module 92
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 91
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 91
Development of an academic disease registry for spinal muscular atrophy 90
An observational study of functional abilities in infants, children, and adults with type 1 SMA 87
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 85
Sleep disorders in spinal muscular atrophy 82
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 81
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 81
Risdiplam in Type 1 Spinal Muscular Atrophy 80
Longitudinal natural history of type I spinal muscular atrophy: A critical review 78
Long term follow-up of scoliosis progression in type II SMA patients 77
Reply to: The need for evidence-based treatment decisions in spinal muscular atrophy type 0 76
An observational study of functional abilities in infants, children, and adults with type 1 SMA 74
Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded 74
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 73
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 73
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 69
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 68
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 68
Revised upper limb module for spinal muscular atrophy: 12 month changes 68
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 65
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 62
Point-of-care lung and diaphragm ultrasound in a patient with spinal muscular atrophy with respiratory distress type 1 62
Erratum: Long term natural history data in ambulant boys with duchenne muscular dystrophy: 36-month changes (PLoS ONE (2015) 10:12 (e0144079)) 60
An observational study of functional abilities in infants, children, and adults with type 1 SMA 59
Ultrasound assessment of diaphragmatic function in type 1 spinal muscular atrophy 55
Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients 55
Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3 46
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool 39
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 18
Totale 7.771
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.200
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.200
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202152 0 0 0 0 0 9 8 2 9 0 23 1
2021/2022398 13 6 5 72 28 11 9 63 26 19 73 73
2022/20231.150 99 150 66 162 76 144 70 104 164 19 55 41
2023/2024992 34 165 34 88 51 172 152 54 19 49 80 94
2024/20251.684 41 24 108 82 134 92 71 67 249 139 374 303
2025/20263.061 524 135 305 591 872 634 0 0 0 0 0 0
Totale 7.771